• Voronoi plans to issue KRW 52.7 billion of unsecured convertible bonds through a private placement on November 23, 2026.
• Proceeds will fund research and development, including VRN11 and VRN10 clinical trials, alongside operating needs.
• The bonds mature November 23, 2031, with a zero coupon and 2% yield to maturity.
• Conversion at KRW 111,510 per share could create 472,603 common shares; the conversion period runs November 23, 2027–October 23, 2031.
• Bondholders can request early redemption starting November 23, 2028, then every three months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voronoi Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261113001035), on November 13, 2026, and is solely responsible for the information contained therein.